Crinetics Pharmaceuticals (CRNX) Free Cash Flow (2017 - 2026)

Crinetics Pharmaceuticals' Free Cash Flow history runs 10 years deep, the most recent figure standing at -$125.2 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 41.09% year-over-year to -$125.2 million in Q1 2026; TTM through Mar 2026 was -$414.8 million, a 54.44% decrease from a year earlier, with the FY2025 full-year figure at -$378.3 million, down 61.65% from the prior year.
• Free Cash Flow slipped to -$125.2 million in Q1 2026 per CRNX's latest filing, from -$93.2 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$13.6 million in Q1 2022 and bottomed at -$125.2 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$46.7 million (2024), against an average of -$60.1 million.
• Across the five-year window, Free Cash Flow jumped 32.15% in 2022 and plunged 198.86% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at -$33.8 million in 2022, then slipped by 21.95% to -$41.3 million in 2023, then plunged by 71.28% to -$70.7 million in 2024, then plunged by 31.96% to -$93.2 million in 2025, then tumbled by 34.25% to -$125.2 million in 2026.
• Per Business Quant, the three latest CRNX Free Cash Flow figures stand at -$125.2 million (Q1 2026), -$93.2 million (Q4 2025), and -$106.3 million (Q3 2025).